Advertisement
ABBV or LLY or MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Eli Lilly (LLY) vs. Merck (MRK) Stock Comparison
Key Takeaways
- ABBV demonstrates resilience with immunology drugs Skyrizi and Rinvoq offsetting Humira declines, posting 9.7% monthly gains amid positive Phase 3 data for SKYRIZI.
- LLY leads growth via Mounjaro and Zepbound, but recent market activity shows YTD declines of around 8% due to sector pricing pressures.
- MRK exhibits strong YTD performance near 10%, driven by Keytruda momentum, though faces Gardasil softness in China.
- All three trade at forward P/E ratios of 12-16x for ABBV and MRK, contrasting LLY's premium valuation over 40x, highlighting value vs. growth trade-offs.
- Dividend yields remain attractive: ABBV at 3%, MRK at 2.7%, supporting defensive positioning in volatile markets.
- Q4 2025 earnings showcased revenue growth across the board, with 2026 guidance signaling mid-single-digit expansion amid patent and competitive challenges.
Introduction
This stock comparison evaluates ABBV, LLY, and MRK—leading biopharmaceutical firms focused on immunology, oncology, diabetes/obesity, and vaccines—in the context of recent market volatility and sector headwinds like pricing reforms. Investors seeking diversified exposure to healthcare growth drivers, including blockbuster drugs and pipeline advancements, will find value in analyzing their relative performance, valuations, and momentum. Traders monitoring pharma relative performance may use this to gauge positioning amid broader equity rotations.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a research-based biopharmaceutical company specializing in immunology, oncology, neuroscience, and aesthetics, with key products like Skyrizi, Rinvoq, Botox, and Vraylar. In recent market activity, ABBV shares have risen about 9.7% over the past month and 8.8% yearly, trading around $230 with a forward P/E of 15.8x and 3% dividend yield. Q4 2025 revenues hit $16.6 billion (up 10%), driven by Skyrizi (+32%) and Rinvoq (+30%) offsetting Humira erosion; full-year sales reached $61.2 billion. Positive Phase 3 AFFIRM results for SKYRIZI in Crohn's disease boosted sentiment, alongside 2026 guidance for $67 billion revenue and adjusted EPS of $14.37–14.57. Performance reflects successful post-Humira transition, though oncology competition tempers gains.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) develops pharmaceuticals in diabetes, obesity, oncology, and immunology, led by Mounjaro and Zepbound. Recent weeks saw LLY shares dip 7.9% monthly and 8% YTD, hovering near $990 despite a forward P/E over 40x and 0.6% yield. Q4 2025 revenues surged 43% to $19.3 billion, with non-GAAP EPS at $7.54; full-year growth was robust. 2026 outlook projects $80–83 billion revenue and EPS of $33.50–35, fueled by incretin demand. Sentiment reflects competitive pressures in obesity treatments and pricing scrutiny, offsetting explosive growth from GLP-1 drugs, with shares underperforming peers short-term amid broader corrections.
MRK Overview and Recent Performance
Merck & Co., Inc. (MRK) is a global healthcare firm emphasizing oncology (Keytruda), vaccines (Gardasil), and animal health. In recent trading, MRK gained nearly 10% YTD and 24% yearly, at about $116 with forward P/E of 12.7x and 2.7% yield. Q4 2025 sales rose 5% to $16.4 billion, non-GAAP EPS $2.04; full-year $65 billion. Keytruda grew steadily, though Gardasil weakened in China. 2026 guidance: $65.5–67 billion revenue, EPS $5–5.15 (including charges). Positive oncology collaborations and pipeline depth support sentiment, balanced by generics risks and reforms.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. AI analyzes all bots to spotlight those best suited to current market conditions, like volatility levels (low, medium, high), with over 25+ featured in growth sectors such as aerospace, energy, semiconductors, and biotech. Stats highlight exceptional performance: annualized returns from +13% to +215%, win rates 52–95%, profit factors 1.6–25.8. Examples include AeroDefense bots at +32–124% annualized with 71–82% win rates on 5–60min timeframes, and multi-ticker strategies up +134% (62% win rate). These encompass swing trading, trend following, and hedging across stocks/ETFs/crypto. Explore Trending AI Robots to identify bots aligning with your style for potential outperformance.
Head-to-Head Comparison
ABBV, LLY, and MRK operate in overlapping pharma segments but diverge in growth drivers: LLY's obesity focus yields highest revenue momentum (43% Q4 growth) versus ABBV (10%) and MRK (5%), though exposes it to competition. ABBV and MRK emphasize diversified immunology/oncology, mitigating single-drug risks like Humira/Keytruda cliffs. Recent momentum favors MRK (YTD +10%) over LLY (-8%), with ABBV stable. Valuation sensitivity shows ABBV/MRK at 14–16x forward P/E (defensive) vs. LLY's 40x+ premium. Risks include pricing reforms for all, but MRK faces China exposure, LLY saturation. Market sentiment tilts toward value stability amid volatility.
Tickeron AI Verdict
Tickeron’s AI currently favors ABBV for its trend consistency in immunology growth, post-Humira stability, attractive valuation, and high dividend yield, positioning it well relative to peers amid sector uncertainties. Probabilistic edges stem from recent positive catalysts like SKYRIZI data and superior monthly momentum versus LLY's volatility and MRK's conservative guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and MRK’s FA Score reflects 4 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- LLY’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s), and MRK’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 5 bullish, 3 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.70% price change this week, while LLY (@Pharmaceuticals: Major) price change was +2.10% , and MRK (@Pharmaceuticals: Major) price fluctuated +1.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
LLY is expected to report earnings on Apr 30, 2026.
MRK is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | LLY | MRK | |
| Capitalization | 376B | 853B | 303B |
| EBITDA | 17.6B | 31.7B | 28.3B |
| Gain YTD | -6.294 | -10.970 | 17.413 |
| P/E Ratio | 89.62 | 41.62 | 16.85 |
| Revenue | 61.2B | 65.2B | 65B |
| Total Cash | 5.26B | 7.27B | N/A |
| Total Debt | 67.5B | 42.5B | 49.3B |
ABBV | LLY | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 10 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 68 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 19 | 43 | |
SMR RATING 1..100 | 1 | 13 | 25 | |
PRICE GROWTH RATING 1..100 | 59 | 55 | 15 | |
P/E GROWTH RATING 1..100 | 40 | 88 | 25 | |
SEASONALITY SCORE 1..100 | 4 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (24) in the Pharmaceuticals Major industry is in the same range as ABBV (38) and is somewhat better than the same rating for LLY (68). This means that MRK's stock grew similarly to ABBV’s and somewhat faster than LLY’s over the last 12 months.
ABBV's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is in the same range as LLY (19) and is in the same range as MRK (43). This means that ABBV's stock grew similarly to LLY’s and similarly to MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as LLY (13) and is in the same range as MRK (25). This means that ABBV's stock grew similarly to LLY’s and similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (55) and is somewhat better than the same rating for ABBV (59). This means that MRK's stock grew somewhat faster than LLY’s and somewhat faster than ABBV’s over the last 12 months.
MRK's P/E Growth Rating (25) in the Pharmaceuticals Major industry is in the same range as ABBV (40) and is somewhat better than the same rating for LLY (88). This means that MRK's stock grew similarly to ABBV’s and somewhat faster than LLY’s over the last 12 months.
| ABBV | LLY | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 33% | 1 day ago 74% | N/A |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 59% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 65% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 62% | 1 day ago 47% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 70% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 57% | 1 day ago 52% |
| Advances ODDS (%) | 1 day ago 57% | 1 day ago 71% | 8 days ago 52% |
| Declines ODDS (%) | 3 days ago 47% | 4 days ago 54% | 3 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 72% | 1 day ago 46% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 56% | 1 day ago 53% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BUFZ | 26.86 | 0.08 | +0.30% |
| FT Vest Laddered Moderate Bffr ETF | |||
| ZAUG | 26.98 | 0.06 | +0.22% |
| Innovator Equity Defined Prt ETF -1YrAug | |||
| MTUL | 35.71 | N/A | N/A |
| ETRACS 2x Lvrgd MSCI US Mntm Fctr TR ETN | |||
| VO | 298.24 | -0.21 | -0.07% |
| Vanguard Mid-Cap ETF | |||
| RSPM | 39.57 | -0.28 | -0.70% |
| Invesco S&P 500® Equal Weight Matrls ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.38% | ||
| BMY - ABBV | 58% Loosely correlated | +0.46% | ||
| PFE - ABBV | 57% Loosely correlated | -0.91% | ||
| BIIB - ABBV | 55% Loosely correlated | -1.55% | ||
| AMGN - ABBV | 53% Loosely correlated | +1.66% | ||
| NVS - ABBV | 52% Loosely correlated | +0.41% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with MRK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then MRK could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRK jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -0.41% | ||
| PFE - MRK | 67% Closely correlated | -0.91% | ||
| BMY - MRK | 63% Loosely correlated | +0.46% | ||
| BIIB - MRK | 59% Loosely correlated | -1.55% | ||
| AMGN - MRK | 57% Loosely correlated | +1.66% | ||
| ABBV - MRK | 56% Loosely correlated | +0.38% | ||
More | ||||